Validated chromatographic method for the simultaneous determination of eight drugs (morphine, ropivacaine, bupivacaine, baclofen, clonidine, sufentanil, fentanyl and ziconotide) for intrathecal analgesia.

[1]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[2]  Xihan Li,et al.  Efficacy and Safety of Ropivacaine Addition to Intrathecal Morphine for Pain Management in Intractable Cancer , 2015, Mediators of inflammation.

[3]  D. Dupoiron,et al.  Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice. , 2015, Pain physician.

[4]  P. Christo,et al.  Current perspectives on intrathecal drug delivery , 2014, Journal of pain research.

[5]  É. Viel,et al.  Techniques analgésiques locorégionales et douleur chronique , 2013 .

[6]  P. Gulur,et al.  Intrathecal Drug Delivery (ITDD) systems for cancer pain , 2013, F1000Research.

[7]  S. Brogan,et al.  Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. , 2011, Pain medicine.

[8]  D. Monnin,et al.  Douleur chronique cancéreuse et analgésie intrathécale : expérience de trois centres de lutte contre le cancer , 2011 .

[9]  K. Ho,et al.  Intrathecal analgesia in patients with cancer pain--an audit in a tertiary institution. , 2009, Annals of the Academy of Medicine, Singapore.

[10]  F. De Conno,et al.  Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  P. Staats,et al.  An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Hassenbusch,et al.  Epidural and intrathecal analgesia is effective in treating refractory cancer pain. , 2004, Pain medicine.

[13]  R. Rauck,et al.  Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. , 2003, Journal of Pain.

[14]  Thomas J. Smith,et al.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Radbruch,et al.  Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology , 2001, Pain.

[16]  John Lynch,et al.  Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study , 1995, Pain.

[17]  C. Cleeland,et al.  Multicentre study of cancer pain and its treatment in France , 1995, BMJ.

[18]  P. Gulur,et al.  Intrathecal Drug Delivery ( ITDD ) systems for cancer pain , 2014 .

[19]  S. Abram.  Intrathecal Treatment in Cancer Patients Unresponsive to Multiple Trials of Systemic Opioids , 2009 .